|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Because human epidermal growth factor receptor 2 (HER2)/ErbB2 is overexpressed in prolactinomas and ErbB receptor ligands regulate prolactin (PRL) gene expression, we tested the role of HER2/ErbB2 in prolactinoma hormone regulation and adenoma cell proliferation to assess the rationale for targeting this receptor for prolactinoma therapy.
|
21106881 |
2011 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thus, the study of PRL gene expression and immunohistochemistry in GH-secreting adenomas is valuable to understanding the pathophysiology of pituitary tumors.
|
2338572 |
1990 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A significantly higher content of CRABP1 mRNA was observed in NFPA compared to functioning adenomas, and PRL-secreting adenomas showed a lower expression of this gene compared to normal pituitary.
|
21270509 |
2011 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition,1 of 2 ACTH tumors but no GH (n = 4) or PRL (n = 1) adenoma examined were hypermethylated.
|
11740049 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Pit-1 mRNA was detected in 12 (80%) of 15 prolactin-producing adenomas.
|
8733768 |
1996 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At last assessment (median follow-up 3 years) and compared with values 6-12 months after stopping DA, Prolactin (PRL) increased in 15%, decreased but not normalized in 33% and was normal in 52%; PRL levels or visible adenoma on imaging before DA withdrawal, treatment duration and presence of macro-/microadenoma at diagnosis were not predictors of normoprolactinaemia at last review, whereas PRL values 6-12 months after stopping DA were.
|
29894000 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Forty-four GH-secreting adenomas, 7 prolactin (PRL)-secreting adenomas and 32 clinically non-functioning adenomas were examined for the presence of point mutations in codon 201 and 227 of the Gs alpha gene using a nested PCR and direct sequencing of DNA extracted from fresh tissue or paraffin-embedded pituitary adenoma samples.
|
11182759 |
2001 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These adenomas included 13 clinically non-functioning adenomas, 1 GH/PRL-producing adenoma, 6 GH-producing adenomas, 2 PRL-producing adenomas and 1 ACTH-producing adenoma.
|
8881451 |
1996 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
|
27708194 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment.
|
16328513 |
2006 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Bromocriptine (BC) is a well known anti-neoplasic agent in human PRL secreting adenomas although its effect on PRL cells is far from clear.
|
11680511 |
2001 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No specific TPIT immunostaining was detectable in all prolactin (PRL)-, GH-, or gonadotropin-secreting adenomas.
|
12843142 |
2003 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histotype of atypical adenomas figured out to be nonfunctioning in 23 cases (46 %), PRL secreting in 10 cases (20 %), ACTH secreting and GH secreting each apart in 8 patients (16 %), and in a single case a GH/PRL secreting adenoma (2 %).
|
27215912 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ptx1 was detected in 10/14 (71.4%) of growth hormone (GH)-secreting adenomas, 12/12 (100%) of prolactin (PRL)-secreting adenomas, 18/20 (90%) of adrenocorticotropic hormone (ACTH)-secreting adenomas, 6/7 (85.7%) of thyroid-stimulating hormone (TSH)-secreting adenomas, and 17/20 (85%) of clinically non-functioning adenomas, including 9/10 (90%) of gonadotropin-subunit-positive adenomas.
|
11048804 |
2000 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
AIP mutation-positive patients have a characteristic clinical phenotype with usually young- or childhood-onset growth hormone (GH) and/or prolactin (PRL)-secreting adenomas and can be seen in cases with no apparent family history as well.
|
23652674 |
2013 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Both are negatively coupled to adenylyl cyclase and inhibit prolactin secretion, but, in addition, the shortest one (D2S) is more efficiently coupled to phospholipase C. Consequently, we also investigated whether expression of a particular D2 receptor isoform was preferentially affected in resistant adenomas.
|
7969790 |
1994 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We also immunostained urocortin in 52 cases of human anterior pituitary adenomas, including GH-producing adenomas (n = 14), ACTH-producing adenomas (n = 13), PRL-producing adenomas (n = 11), and nonfunctioning hormonally inactive adenomas (n = 14).
|
9360550 |
1997 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Prolactinomas, or prolactin-secreting adenomas, constitute the most common type of hyperfunctioning pituitary adenoma.
|
24135847 |
2014 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Regarding tumor type, adrenocorticotropic hormone (ACTH), prolactin (PRL), growth hormone (GH), non-functioning and multiple-secreting adenomas accounted for 35.7%, 25.7%, 12.2%, 25.7%, and 0.7% of the tumors, respectively.
|
31376772 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Five ACTH producing adenomas, 11 GH producing adenomas, one PRL producing adenoma and five non-functioning adenomas were obtained at surgery.
|
7923822 |
1994 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparing ISH with immunohistology (IH) we found a correlation between signals and hormone content in 100% of adenomas for GH, in 60% for Prolactin and in 10% for Gonadotropins.
|
1923947 |
1991 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
|
30400048 |
2019 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In cells cultured from the 10 mixed adenomas that secreted both GH and PRL, RT-PCR analysis revealed a consistent coexpression of SSTR5, SSTR2, and SSTR1 mRNA.
|
10690891 |
2000 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The functional differentiation of pituitary cells and adenomas follows the combination of transcription factors and co-factors in three cell lineages [growth hormone-prolactin-thyroid-stimulating hormone lineage, adrenocorticotrophic hormone (ACTH)/pro-opiomelanocortin (POMC) lineage, and follicular stimulating hormone (FSH)/luteinizing hormone (LH) lineage], which include Pit-1, GATA-2, SF-1, NeuroD1/beta2, Tpit, ERalpha, and others.
|
18228160 |
2008 |